SEC Form 4 · accession 0000850261-18-000029

Sorrento Therapeutics, Inc. · SRNE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks · Director

Period of report

Jul 20, 2018

Accepted (ET)

Jul 23, 2018 · 6:50 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000850261

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 20, 2018	M	6,000	$1.75	A	2,045,807	D
Common Stock^F1,F2	holding	—	—		—	2,271,693	I	See Footnote
Common Stock^F1	holding	—	—		—	40,000	I	By spouse

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock^F3	$1.75	Jul 20, 2018	M	6,000	D	—	Feb 16, 2020	Common Stock	6,000	0	D

F1Since February 28, 2018, the date of the Reporting Person's last Form 4 disclosing holdings under Table I of Form 4 (the "Prior Form 4"), the Reporting Person has transferred shares of Common Stock among his direct holdings, the holdings of his spouse, the holdings of family trusts of which the Reporting Person is co-trustee with his spouse and the holdings of an entity of which the Reporting Person and his spouse are the sole members and managing directors. 2,999 shares of Common Stock beneficially owned by the Reporting Person were also inadvertently omitted from the Prior Form 4.
F2Shares are held in family trusts of which the Reporting Person is a co-trustee with his spouse.
F3This option vested over a four-year period commencing on February 16, 2010, with 25% of the shares subject to the option vesting on each anniversary of the vesting commencement date. The shares were fully vested as of February 16, 2014.

President, CEO and Chairman of the Board of Directors